Drugs / INO-5401
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04367675 | Apr 2021 → Dec 2026 expected | hereditary neoplastic syndrome | Abramson Cancer Center at Penn Medicine | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03491683 | May 2018 → Dec 2026 expected | glioblastoma | Inovio Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03502785 | May 2018 → May 2025 | urothelial carcinoma | Inovio Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-5401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03491683 ↗ |
| Modality | Other / unclassified | “INO-5401 is a combination of 3 separate DNA plasmids” NCT03491683 ↗ |
| Route | Intramuscular | “will be delivered IM followed by EP” NCT03491683 ↗ |
| Target | WT1 | “targeting Wilms tumor gene-1 (WT1) antigen” NCT03491683 ↗ |